AI Article Synopsis
- The growth of cancer immunology and immunotherapy is largely due to the effectiveness of immune checkpoint inhibitors and chimeric antigen receptor T cells for certain cancers.
- There are still significant gaps in understanding how immune dysfunction occurs in tumor environments and how to accurately predict which patients will respond to immunotherapy.
- The Cancer Immunotherapy Collection includes important preclinical and clinical research that provides valuable insights and advancements in addressing these challenges.
Article Abstract
The rapid expansion of cancer immunology and immunotherapy builds upon the success of early immune checkpoint inhibitors (ICI) and chimeric antigen receptor T cells for some cancer types. Many gaps still exist, however, in the scientific knowledge of immune dysfunction in the tumour microenvironment and predicting clinical immunotherapy response to allow more cancer patients to benefit from immunotherapy. The Cancer Immunotherapy Collection within describes pioneering preclinical and clinical studies addressing these concepts, representing significant insights and breakthroughs in the field.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10786836 | PMC |
| http://dx.doi.org/10.1038/s41598-024-51704-5 | DOI Listing |
Publication Analysis
Top Keywords
cancer immunotherapy
8
immunotherapy
5
advancing cancer
4
immunotherapy innovative
4
innovative preclinical
4
preclinical models
4
models clinical
4
clinical insights
4
insights rapid
4
rapid expansion
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!